Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
Identifieur interne : 000042 ( Main/Exploration ); précédent : 000041; suivant : 000043Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
Auteurs : Laure-Anne Van Bellinghen [Belgique] ; Alen Marijam [Belgique] ; Gabriela Tannus Branco De Araujo [Brésil] ; Jorge Gomez [Argentine] ; Ilse Van Vlaenderen [Belgique]Source :
- The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [ 1678-4391 ]
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse coût-bénéfice (méthodes), Analyse coût-bénéfice (statistiques et données numériques), Années de vie ajustées sur la qualité (MeSH), Appréciation des risques (MeSH), Brésil (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Facteurs âges (MeSH), Femelle (MeSH), Grippe humaine (mortalité), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Hospitalisation (économie), Humains (MeSH), Jeune adulte (MeSH), Modèles économiques (MeSH), Mâle (MeSH), Nourrisson (MeSH), Reproductibilité des résultats (MeSH), Sujet âgé (MeSH), Techniques d'aide à la décision (MeSH), Vaccination (statistiques et données numériques), Vaccination (économie), Vaccins antigrippaux (économie).
- MESH :
- mortalité : Grippe humaine.
- méthodes : Analyse coût-bénéfice.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Analyse coût-bénéfice, Vaccination.
- économie : Grippe humaine, Hospitalisation, Vaccination, Vaccins antigrippaux.
- Adolescent, Adulte, Adulte d'âge moyen, Années de vie ajustées sur la qualité, Appréciation des risques, Brésil, Enfant, Enfant d'âge préscolaire, Facteurs âges, Femelle, Humains, Jeune adulte, Modèles économiques, Mâle, Nourrisson, Reproductibilité des résultats, Sujet âgé, Techniques d'aide à la décision.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Age Factors (MeSH), Aged (MeSH), Brazil (MeSH), Child (MeSH), Child, Preschool (MeSH), Cost-Benefit Analysis (methods), Cost-Benefit Analysis (statistics & numerical data), Decision Support Techniques (MeSH), Female (MeSH), Hospitalization (economics), Humans (MeSH), Infant (MeSH), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (mortality), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Models, Economic (MeSH), Quality-Adjusted Life Years (MeSH), Reproducibility of Results (MeSH), Risk Assessment (MeSH), Vaccination (economics), Vaccination (statistics & numerical data), Young Adult (MeSH).
- MESH :
- chemical , economics : Influenza Vaccines.
- economics : Hospitalization, Influenza, Human, Vaccination.
- methods : Cost-Benefit Analysis.
- mortality : Influenza, Human.
- prevention & control : Influenza, Human.
- statistics & numerical data : Cost-Benefit Analysis, Vaccination.
- Adolescent, Adult, Age Factors, Aged, Brazil, Child, Child, Preschool, Decision Support Techniques, Female, Humans, Infant, Male, Middle Aged, Models, Economic, Quality-Adjusted Life Years, Reproducibility of Results, Risk Assessment, Young Adult.
Abstract
BACKGROUND
Influenza burden in Brazil is considerable with 4.2-6.4 million cases in 2008 and influenza-like-illness responsible for 16.9% of hospitalizations. Cost-effectiveness of influenza vaccination may be assessed by different types of models, with limitations due to data availability, assumptions, and modelling approach.
OBJECTIVE
To understand the impact of model complexity, the cost-utility of quadrivalent versus trivalent influenza vaccines in Brazil was estimated using three distinct models: a 1-year decision tree population model with three age groups (FLOU); a more detailed 1-year population model with five age groups (FLORA); and a more complex lifetime multi-cohort Markov model with nine age groups (FLORENCE).
METHODS
Analysis 1 (impact of model structure) compared each model using the same data inputs (i.e., best available data for FLOU). Analysis 2 (impact of increasing granularity) compared each model populated with the best available data for that model.
RESULTS
Using the best data for each model, the discounted cost-utility ratio of quadrivalent versus trivalent influenza vaccine was R$20,428 with FLOU, R$22,768 with FLORA (versus R$20,428 in Analysis 1), and, R$19,257 with FLORENCE (versus R$22,490 in Analysis 1) using a lifetime horizon. Conceptual differences between FLORA and FLORENCE meant the same assumption regarding increased all-cause mortality in at-risk individuals had an opposite effect on the incremental cost-effectiveness ratio in Analysis 2 versus 1, and a proportionally higher number of vaccinated elderly in FLORENCE reduced this ratio in Analysis 2.
DISCUSSION
FLOU provided adequate cost-effectiveness estimates with data in broad age groups. FLORA increased insights (e.g., in healthy versus at-risk, paediatric, respiratory/non-respiratory complications). FLORENCE provided greater insights and precision (e.g., in elderly, costs and complications, lifetime cost-effectiveness).
CONCLUSION
All three models predicted a cost per quality-adjusted life year gained for quadrivalent versus trivalent influenza vaccine in the range of R$19,257 (FLORENCE) to R$22,768 (FLORA) with the best available data in Brazil (Appendix A).
DOI: 10.1016/j.bjid.2017.11.004
PubMed: 29352897
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.</title><author><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name><affiliation wicri:level="1"><nlm:affiliation>CHESS in Health, Bonheiden, Belgium. Electronic address: lvanbellinghen@chessinhealth.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>CHESS in Health, Bonheiden</wicri:regionArea><wicri:noRegion>Bonheiden</wicri:noRegion></affiliation></author><author><name sortKey="Marijam, Alen" sort="Marijam, Alen" uniqKey="Marijam A" first="Alen" last="Marijam">Alen Marijam</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Tannus Branco De Araujo, Gabriela" sort="Tannus Branco De Araujo, Gabriela" uniqKey="Tannus Branco De Araujo G" first="Gabriela" last="Tannus Branco De Araujo">Gabriela Tannus Branco De Araujo</name><affiliation wicri:level="2"><nlm:affiliation>AxiaBio, São Paulo, SP, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>AxiaBio, São Paulo, SP</wicri:regionArea><placeName><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Gomez, Jorge" sort="Gomez, Jorge" uniqKey="Gomez J" first="Jorge" last="Gomez">Jorge Gomez</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Victoria, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>GSK, Victoria, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name><affiliation wicri:level="1"><nlm:affiliation>CHESS in Health, Bonheiden, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>CHESS in Health, Bonheiden</wicri:regionArea><wicri:noRegion>Bonheiden</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018 Jan - Feb</date><idno type="RBID">pubmed:29352897</idno><idno type="pmid">29352897</idno><idno type="doi">10.1016/j.bjid.2017.11.004</idno><idno type="wicri:Area/Main/Corpus">000055</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000055</idno><idno type="wicri:Area/Main/Curation">000055</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000055</idno><idno type="wicri:Area/Main/Exploration">000055</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.</title><author><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name><affiliation wicri:level="1"><nlm:affiliation>CHESS in Health, Bonheiden, Belgium. Electronic address: lvanbellinghen@chessinhealth.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>CHESS in Health, Bonheiden</wicri:regionArea><wicri:noRegion>Bonheiden</wicri:noRegion></affiliation></author><author><name sortKey="Marijam, Alen" sort="Marijam, Alen" uniqKey="Marijam A" first="Alen" last="Marijam">Alen Marijam</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GSK, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Tannus Branco De Araujo, Gabriela" sort="Tannus Branco De Araujo, Gabriela" uniqKey="Tannus Branco De Araujo G" first="Gabriela" last="Tannus Branco De Araujo">Gabriela Tannus Branco De Araujo</name><affiliation wicri:level="2"><nlm:affiliation>AxiaBio, São Paulo, SP, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>AxiaBio, São Paulo, SP</wicri:regionArea><placeName><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Gomez, Jorge" sort="Gomez, Jorge" uniqKey="Gomez J" first="Jorge" last="Gomez">Jorge Gomez</name><affiliation wicri:level="1"><nlm:affiliation>GSK, Victoria, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>GSK, Victoria, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name><affiliation wicri:level="1"><nlm:affiliation>CHESS in Health, Bonheiden, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>CHESS in Health, Bonheiden</wicri:regionArea><wicri:noRegion>Bonheiden</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases</title><idno type="eISSN">1678-4391</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Brazil (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Cost-Benefit Analysis (methods)</term><term>Cost-Benefit Analysis (statistics & numerical data)</term><term>Decision Support Techniques (MeSH)</term><term>Female (MeSH)</term><term>Hospitalization (economics)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Models, Economic (MeSH)</term><term>Quality-Adjusted Life Years (MeSH)</term><term>Reproducibility of Results (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Vaccination (economics)</term><term>Vaccination (statistics & numerical data)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse coût-bénéfice (méthodes)</term><term>Analyse coût-bénéfice (statistiques et données numériques)</term><term>Années de vie ajustées sur la qualité (MeSH)</term><term>Appréciation des risques (MeSH)</term><term>Brésil (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Hospitalisation (économie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Modèles économiques (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Reproductibilité des résultats (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Techniques d'aide à la décision (MeSH)</term><term>Vaccination (statistiques et données numériques)</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Hospitalization</term><term>Influenza, Human</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cost-Benefit Analysis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Analyse coût-bénéfice</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Hospitalisation</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Brazil</term><term>Child</term><term>Child, Preschool</term><term>Decision Support Techniques</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Models, Economic</term><term>Quality-Adjusted Life Years</term><term>Reproducibility of Results</term><term>Risk Assessment</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Années de vie ajustées sur la qualité</term><term>Appréciation des risques</term><term>Brésil</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs âges</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Modèles économiques</term><term>Mâle</term><term>Nourrisson</term><term>Reproductibilité des résultats</term><term>Sujet âgé</term><term>Techniques d'aide à la décision</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Influenza burden in Brazil is considerable with 4.2-6.4 million cases in 2008 and influenza-like-illness responsible for 16.9% of hospitalizations. Cost-effectiveness of influenza vaccination may be assessed by different types of models, with limitations due to data availability, assumptions, and modelling approach.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To understand the impact of model complexity, the cost-utility of quadrivalent versus trivalent influenza vaccines in Brazil was estimated using three distinct models: a 1-year decision tree population model with three age groups (FLOU); a more detailed 1-year population model with five age groups (FLORA); and a more complex lifetime multi-cohort Markov model with nine age groups (FLORENCE).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Analysis 1 (impact of model structure) compared each model using the same data inputs (i.e., best available data for FLOU). Analysis 2 (impact of increasing granularity) compared each model populated with the best available data for that model.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Using the best data for each model, the discounted cost-utility ratio of quadrivalent versus trivalent influenza vaccine was R$20,428 with FLOU, R$22,768 with FLORA (versus R$20,428 in Analysis 1), and, R$19,257 with FLORENCE (versus R$22,490 in Analysis 1) using a lifetime horizon. Conceptual differences between FLORA and FLORENCE meant the same assumption regarding increased all-cause mortality in at-risk individuals had an opposite effect on the incremental cost-effectiveness ratio in Analysis 2 versus 1, and a proportionally higher number of vaccinated elderly in FLORENCE reduced this ratio in Analysis 2.</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>FLOU provided adequate cost-effectiveness estimates with data in broad age groups. FLORA increased insights (e.g., in healthy versus at-risk, paediatric, respiratory/non-respiratory complications). FLORENCE provided greater insights and precision (e.g., in elderly, costs and complications, lifetime cost-effectiveness).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>All three models predicted a cost per quality-adjusted life year gained for quadrivalent versus trivalent influenza vaccine in the range of R$19,257 (FLORENCE) to R$22,768 (FLORA) with the best available data in Brazil (Appendix A).</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29352897</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4391</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><MedlineDate>2018 Jan - Feb</MedlineDate></PubDate></JournalIssue><Title>The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases</Title><ISOAbbreviation>Braz J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.</ArticleTitle><Pagination><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1413-8670(17)30654-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bjid.2017.11.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza burden in Brazil is considerable with 4.2-6.4 million cases in 2008 and influenza-like-illness responsible for 16.9% of hospitalizations. Cost-effectiveness of influenza vaccination may be assessed by different types of models, with limitations due to data availability, assumptions, and modelling approach.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To understand the impact of model complexity, the cost-utility of quadrivalent versus trivalent influenza vaccines in Brazil was estimated using three distinct models: a 1-year decision tree population model with three age groups (FLOU); a more detailed 1-year population model with five age groups (FLORA); and a more complex lifetime multi-cohort Markov model with nine age groups (FLORENCE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Analysis 1 (impact of model structure) compared each model using the same data inputs (i.e., best available data for FLOU). Analysis 2 (impact of increasing granularity) compared each model populated with the best available data for that model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using the best data for each model, the discounted cost-utility ratio of quadrivalent versus trivalent influenza vaccine was R$20,428 with FLOU, R$22,768 with FLORA (versus R$20,428 in Analysis 1), and, R$19,257 with FLORENCE (versus R$22,490 in Analysis 1) using a lifetime horizon. Conceptual differences between FLORA and FLORENCE meant the same assumption regarding increased all-cause mortality in at-risk individuals had an opposite effect on the incremental cost-effectiveness ratio in Analysis 2 versus 1, and a proportionally higher number of vaccinated elderly in FLORENCE reduced this ratio in Analysis 2.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">FLOU provided adequate cost-effectiveness estimates with data in broad age groups. FLORA increased insights (e.g., in healthy versus at-risk, paediatric, respiratory/non-respiratory complications). FLORENCE provided greater insights and precision (e.g., in elderly, costs and complications, lifetime cost-effectiveness).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">All three models predicted a cost per quality-adjusted life year gained for quadrivalent versus trivalent influenza vaccine in the range of R$19,257 (FLORENCE) to R$22,768 (FLORA) with the best available data in Brazil (Appendix A).</AbstractText><CopyrightInformation>Copyright © 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Bellinghen</LastName><ForeName>Laure-Anne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>CHESS in Health, Bonheiden, Belgium. Electronic address: lvanbellinghen@chessinhealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marijam</LastName><ForeName>Alen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GSK, Wavre, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tannus Branco de Araujo</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AxiaBio, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>GSK, Victoria, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Vlaenderen</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CHESS in Health, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Infect Dis</MedlineTA><NlmUniqueID>9812937</NlmUniqueID><ISSNLinking>1413-8670</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brazil</Keyword><Keyword MajorTopicYN="N">Cost-effectiveness</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">QIV</Keyword><Keyword MajorTopicYN="N">TIV</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29352897</ArticleId><ArticleId IdType="pii">S1413-8670(17)30654-2</ArticleId><ArticleId IdType="doi">10.1016/j.bjid.2017.11.004</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Argentine</li><li>Belgique</li><li>Brésil</li></country><region><li>État de São Paulo</li></region></list><tree><country name="Belgique"><noRegion><name sortKey="Van Bellinghen, Laure Anne" sort="Van Bellinghen, Laure Anne" uniqKey="Van Bellinghen L" first="Laure-Anne" last="Van Bellinghen">Laure-Anne Van Bellinghen</name></noRegion><name sortKey="Marijam, Alen" sort="Marijam, Alen" uniqKey="Marijam A" first="Alen" last="Marijam">Alen Marijam</name><name sortKey="Van Vlaenderen, Ilse" sort="Van Vlaenderen, Ilse" uniqKey="Van Vlaenderen I" first="Ilse" last="Van Vlaenderen">Ilse Van Vlaenderen</name></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Tannus Branco De Araujo, Gabriela" sort="Tannus Branco De Araujo, Gabriela" uniqKey="Tannus Branco De Araujo G" first="Gabriela" last="Tannus Branco De Araujo">Gabriela Tannus Branco De Araujo</name></region></country><country name="Argentine"><noRegion><name sortKey="Gomez, Jorge" sort="Gomez, Jorge" uniqKey="Gomez J" first="Jorge" last="Gomez">Jorge Gomez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeBresilV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000042 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000042 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeBresilV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29352897
|texte= Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29352897" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeBresilV2
| This area was generated with Dilib version V0.6.36. |  |